{"id": "article-27416_0", "title": "Polymyalgia Rheumatica -- Continuing Education Activity", "content": "Polymyalgia rheumatica (PMR) is a rheumatic disorder characterized by pain and stiffness around the neck, shoulder, and hip area. This disorder is more common in White adults older than 50 years of age. It is an inflammatory condition associated with an elevation of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), being the common findings. PMR patients can develop or have concomitant giant cell arteritis (GCA). Some authors consider GCA an extreme entity of the same spectrum of disorders as PMR.", "contents": "Polymyalgia Rheumatica -- Continuing Education Activity. Polymyalgia rheumatica (PMR) is a rheumatic disorder characterized by pain and stiffness around the neck, shoulder, and hip area. This disorder is more common in White adults older than 50 years of age. It is an inflammatory condition associated with an elevation of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), being the common findings. PMR patients can develop or have concomitant giant cell arteritis (GCA). Some authors consider GCA an extreme entity of the same spectrum of disorders as PMR."}
{"id": "article-27416_1", "title": "Polymyalgia Rheumatica -- Continuing Education Activity", "content": "Clinicians participating in this activity can expect to gain a comprehensive understanding of PMR, including its clinical manifestations, association with GCA, and challenges in diagnosis and long-term management. The activity emphasizes the role of the interprofessional team in effectively addressing the complexities of PMR, providing valuable insights into improved patient care and outcomes. Topics covered include the cause, pathophysiology, and presentation of PMR, empowering clinicians with the knowledge and skills to navigate the intricacies of this inflammatory disorder in older adults.", "contents": "Polymyalgia Rheumatica -- Continuing Education Activity. Clinicians participating in this activity can expect to gain a comprehensive understanding of PMR, including its clinical manifestations, association with GCA, and challenges in diagnosis and long-term management. The activity emphasizes the role of the interprofessional team in effectively addressing the complexities of PMR, providing valuable insights into improved patient care and outcomes. Topics covered include the cause, pathophysiology, and presentation of PMR, empowering clinicians with the knowledge and skills to navigate the intricacies of this inflammatory disorder in older adults."}
{"id": "article-27416_2", "title": "Polymyalgia Rheumatica -- Continuing Education Activity", "content": "Objectives: Identify the etiology of polymyalgia rheumatica. Differentiate polymyalgia rheumatica from other rheumatic conditions through a comprehensive understanding of its clinical manifestations, laboratory findings, and imaging studies. Implement evidence-based treatment strategies for managing patients with polymyalgia rheumatica. Collaborate with an interprofessional healthcare team\u00a0to optimize comprehensive care for patients with polymyalgia rheumatica. Access free multiple choice questions on this topic.", "contents": "Polymyalgia Rheumatica -- Continuing Education Activity. Objectives: Identify the etiology of polymyalgia rheumatica. Differentiate polymyalgia rheumatica from other rheumatic conditions through a comprehensive understanding of its clinical manifestations, laboratory findings, and imaging studies. Implement evidence-based treatment strategies for managing patients with polymyalgia rheumatica. Collaborate with an interprofessional healthcare team\u00a0to optimize comprehensive care for patients with polymyalgia rheumatica. Access free multiple choice questions on this topic."}
{"id": "article-27416_3", "title": "Polymyalgia Rheumatica -- Introduction", "content": "Polymyalgia rheumatica (PMR) is a rheumatic disorder characterized by pain and stiffness around the neck, shoulder, and hip area that significantly impacts quality of life. This disorder is more common in\u00a0white adults over 50 years of age. It is an inflammatory\u00a0condition associated with an elevation of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), being the typical findings. Patients with PMR can develop or have concomitant giant cell arteritis (GCA), \u00a0also known as Horton disease. Some authors consider GCA an extreme entity of the same spectrum of disorders as PMR.", "contents": "Polymyalgia Rheumatica -- Introduction. Polymyalgia rheumatica (PMR) is a rheumatic disorder characterized by pain and stiffness around the neck, shoulder, and hip area that significantly impacts quality of life. This disorder is more common in\u00a0white adults over 50 years of age. It is an inflammatory\u00a0condition associated with an elevation of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), being the typical findings. Patients with PMR can develop or have concomitant giant cell arteritis (GCA), \u00a0also known as Horton disease. Some authors consider GCA an extreme entity of the same spectrum of disorders as PMR."}
{"id": "article-27416_4", "title": "Polymyalgia Rheumatica -- Introduction", "content": "Understanding the intricacies of PMR is essential for clinicians, as it requires a nuanced approach to management, including careful consideration of the potential long-term complications and the crucial interplay with GCA. This review aims to highlight the key aspects of PMR,\u00a0including the etiology, clinical features, and optimal management strategies.", "contents": "Polymyalgia Rheumatica -- Introduction. Understanding the intricacies of PMR is essential for clinicians, as it requires a nuanced approach to management, including careful consideration of the potential long-term complications and the crucial interplay with GCA. This review aims to highlight the key aspects of PMR,\u00a0including the etiology, clinical features, and optimal management strategies."}
{"id": "article-27416_5", "title": "Polymyalgia Rheumatica -- Etiology", "content": "The etiology of\u00a0PMR is not well-understood.", "contents": "Polymyalgia Rheumatica -- Etiology. The etiology of\u00a0PMR is not well-understood."}
{"id": "article-27416_6", "title": "Polymyalgia Rheumatica -- Etiology", "content": "Familial aggregation of PMR\u00a0has suggested a genetic predisposition. [1] HLA class II alleles are found to be\u00a0associated with PMR, and among these, the HLA-DRB1*04 allele correlates most frequently, seen in up to 67% of cases. [2] Genetic polymorphisms for ICAM-1, RANTES, and IL-1 receptors also appear to play a role in the pathogenesis of PMR in some populations. [3]", "contents": "Polymyalgia Rheumatica -- Etiology. Familial aggregation of PMR\u00a0has suggested a genetic predisposition. [1] HLA class II alleles are found to be\u00a0associated with PMR, and among these, the HLA-DRB1*04 allele correlates most frequently, seen in up to 67% of cases. [2] Genetic polymorphisms for ICAM-1, RANTES, and IL-1 receptors also appear to play a role in the pathogenesis of PMR in some populations. [3]"}
{"id": "article-27416_7", "title": "Polymyalgia Rheumatica -- Etiology", "content": "There were reports of increased incidence of PMR along with GCA during epidemics of mycoplasma pneumonia and parvovirus B19 in Denmark, suggesting a possible role of infection in etiopathogenesis. [4] The Epstein-Barr virus (EBV) has also\u00a0been proposed as a possible\u00a0trigger for PMR. [5] However, several other studies have not supported an infectious etiology hypothesis. [6] [7]", "contents": "Polymyalgia Rheumatica -- Etiology. There were reports of increased incidence of PMR along with GCA during epidemics of mycoplasma pneumonia and parvovirus B19 in Denmark, suggesting a possible role of infection in etiopathogenesis. [4] The Epstein-Barr virus (EBV) has also\u00a0been proposed as a possible\u00a0trigger for PMR. [5] However, several other studies have not supported an infectious etiology hypothesis. [6] [7]"}
{"id": "article-27416_8", "title": "Polymyalgia Rheumatica -- Etiology", "content": "There are also reports of an association between PMR and diverticulitis, which could suggest a role of a change in microbiota and chronic\u00a0bowel inflammation in\u00a0the immunopathogenesis of the disease. [8]", "contents": "Polymyalgia Rheumatica -- Etiology. There are also reports of an association between PMR and diverticulitis, which could suggest a role of a change in microbiota and chronic\u00a0bowel inflammation in\u00a0the immunopathogenesis of the disease. [8]"}
{"id": "article-27416_9", "title": "Polymyalgia Rheumatica -- Etiology", "content": "A case series of\u00a0previously healthy subjects developing GCA/PMR after\u00a0influenza vaccination also exists. [9] Vaccine adjuvants can trigger autoimmunity-causing autoimmune/inflammatory syndrome induced by adjuvants (ASIA), which can have clinical features similar to PMR.", "contents": "Polymyalgia Rheumatica -- Etiology. A case series of\u00a0previously healthy subjects developing GCA/PMR after\u00a0influenza vaccination also exists. [9] Vaccine adjuvants can trigger autoimmunity-causing autoimmune/inflammatory syndrome induced by adjuvants (ASIA), which can have clinical features similar to PMR."}
{"id": "article-27416_10", "title": "Polymyalgia Rheumatica -- Epidemiology", "content": "The annual incidence of\u00a0PMR\u00a0in individuals aged 50 years or older was found to be between\u00a058 to 96 per 100,000 population, specifically predominantly White populations.\u00a0Incidence rates increase with age until 80 years. [10] [11]", "contents": "Polymyalgia Rheumatica -- Epidemiology. The annual incidence of\u00a0PMR\u00a0in individuals aged 50 years or older was found to be between\u00a058 to 96 per 100,000 population, specifically predominantly White populations.\u00a0Incidence rates increase with age until 80 years. [10] [11]"}
{"id": "article-27416_11", "title": "Polymyalgia Rheumatica -- Epidemiology", "content": "PMR has been\u00a0reported as the second most common inflammatory autoimmune rheumatic disease after rheumatoid arthritis in some predominantly White populations. It is at least twice as common as GCA and is found in approximately 50% of patients with GCA. [12] PMR is much less common in Black, Asian, and Hispanic populations.", "contents": "Polymyalgia Rheumatica -- Epidemiology. PMR has been\u00a0reported as the second most common inflammatory autoimmune rheumatic disease after rheumatoid arthritis in some predominantly White populations. It is at least twice as common as GCA and is found in approximately 50% of patients with GCA. [12] PMR is much less common in Black, Asian, and Hispanic populations."}
{"id": "article-27416_12", "title": "Polymyalgia Rheumatica -- Pathophysiology", "content": "PMR is an immune-mediated disorder, and elevated inflammatory markers are common. IL-6 is key in mediating inflammation and is elevated in both PMR and GCA. [13] Interferon (IFN) may be present in temporal artery biopsies in patients with GCA but not in patients with PMR, suggesting its role in the development of arteritis. [14]", "contents": "Polymyalgia Rheumatica -- Pathophysiology. PMR is an immune-mediated disorder, and elevated inflammatory markers are common. IL-6 is key in mediating inflammation and is elevated in both PMR and GCA. [13] Interferon (IFN) may be present in temporal artery biopsies in patients with GCA but not in patients with PMR, suggesting its role in the development of arteritis. [14]"}
{"id": "article-27416_13", "title": "Polymyalgia Rheumatica -- Pathophysiology", "content": "An elevated IgG4 level was\u00a0found in patients with PMR but less frequently in patients with GCA. [15] The same study discovered an increased number of patients with PMR features without\u00a0elevation\u00a0of\u00a0IgG4 disease\u00a0to have simultaneous GCA.", "contents": "Polymyalgia Rheumatica -- Pathophysiology. An elevated IgG4 level was\u00a0found in patients with PMR but less frequently in patients with GCA. [15] The same study discovered an increased number of patients with PMR features without\u00a0elevation\u00a0of\u00a0IgG4 disease\u00a0to have simultaneous GCA."}
{"id": "article-27416_14", "title": "Polymyalgia Rheumatica -- Pathophysiology", "content": "Patients with PMR have a decreased number of circulating B cells compared to healthy adults. The circulating B cell number inversely correlates with ESR and CRP. This altered distribution of B cells possibly contributes to the IL-6 response in PMR. [16]", "contents": "Polymyalgia Rheumatica -- Pathophysiology. Patients with PMR have a decreased number of circulating B cells compared to healthy adults. The circulating B cell number inversely correlates with ESR and CRP. This altered distribution of B cells possibly contributes to the IL-6 response in PMR. [16]"}
{"id": "article-27416_15", "title": "Polymyalgia Rheumatica -- Pathophysiology", "content": "Autoantibodies with a significant role in pathogenesis are not a feature of PMR. Like GCA, patients with PMR also have decreased\u00a0regulatory T (Treg) cells and T helper (Th)1 cells and increased\u00a0Th17 cells. [17] Some studies have suggested a cyclical pattern of\u00a0GCA and PMR in seasonal variation and incidence, implying possible environmental triggers. [18] Increased expression of toll-like receptors 7 and 9 in peripheral blood monocytes suggests the role of innate immunity in pathogenesis\u00a0as well. [19]", "contents": "Polymyalgia Rheumatica -- Pathophysiology. Autoantibodies with a significant role in pathogenesis are not a feature of PMR. Like GCA, patients with PMR also have decreased\u00a0regulatory T (Treg) cells and T helper (Th)1 cells and increased\u00a0Th17 cells. [17] Some studies have suggested a cyclical pattern of\u00a0GCA and PMR in seasonal variation and incidence, implying possible environmental triggers. [18] Increased expression of toll-like receptors 7 and 9 in peripheral blood monocytes suggests the role of innate immunity in pathogenesis\u00a0as well. [19]"}
{"id": "article-27416_16", "title": "Polymyalgia Rheumatica -- History and Physical", "content": "PMR characteristically demonstrates symmetrical pain and stiffness in and around the shoulders, neck, and hip girdle. Pain and stiffness (lasting\u00a0longer than 45 minutes) are the worst in the morning and worsen after rest or prolonged inactivity. Restricted range of motion of the shoulders is common.\u00a0Patients often complain of pain and stiffness in the upper arms, hips, thighs, and upper and lower back. The onset of symptoms is rapid, usually from\u00a0a\u00a0day up to\u00a02 weeks. It affects the quality of life as the pain may impair sleep at nighttime and daytime routine activities like getting out of bed or a chair, hooking a bra in the back, donning socks and shoes, taking a shower, hair brushing, driving, etc. [20]", "contents": "Polymyalgia Rheumatica -- History and Physical. PMR characteristically demonstrates symmetrical pain and stiffness in and around the shoulders, neck, and hip girdle. Pain and stiffness (lasting\u00a0longer than 45 minutes) are the worst in the morning and worsen after rest or prolonged inactivity. Restricted range of motion of the shoulders is common.\u00a0Patients often complain of pain and stiffness in the upper arms, hips, thighs, and upper and lower back. The onset of symptoms is rapid, usually from\u00a0a\u00a0day up to\u00a02 weeks. It affects the quality of life as the pain may impair sleep at nighttime and daytime routine activities like getting out of bed or a chair, hooking a bra in the back, donning socks and shoes, taking a shower, hair brushing, driving, etc. [20]"}
{"id": "article-27416_17", "title": "Polymyalgia Rheumatica -- History and Physical", "content": "The pain and stiffness associated with PMR are most probably related to inflammation of the glenohumeral and hip joints and the subacromial, subdeltoid, and trochanteric bursae in the upper extremities. [21] Almost up to half of the patients experience systemic symptoms like fatigue, malaise, anorexia, weight loss, and/or low-grade fever. [22] Persistent high fever is uncommon in PMR and should alert suspicion of GCA. [23]", "contents": "Polymyalgia Rheumatica -- History and Physical. The pain and stiffness associated with PMR are most probably related to inflammation of the glenohumeral and hip joints and the subacromial, subdeltoid, and trochanteric bursae in the upper extremities. [21] Almost up to half of the patients experience systemic symptoms like fatigue, malaise, anorexia, weight loss, and/or low-grade fever. [22] Persistent high fever is uncommon in PMR and should alert suspicion of GCA. [23]"}
{"id": "article-27416_18", "title": "Polymyalgia Rheumatica -- History and Physical", "content": "Peripheral involvement is also frequent with arthritis in a fourth\u00a0of patients. Other peripheral features like carpal tunnel syndrome, distal extremity swelling with pitting edema, and distal tenosynovitis can be present. Arthritis does not lead to erosions, deformities, or the development of rheumatoid arthritis. [24] Distal extremity swelling with pitting edema responds promptly to glucocorticoids. [25] An unusual distal manifestation is puffy edematous hand syndrome or remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome, comprised of explosive and abrupt clinical symptoms.", "contents": "Polymyalgia Rheumatica -- History and Physical. Peripheral involvement is also frequent with arthritis in a fourth\u00a0of patients. Other peripheral features like carpal tunnel syndrome, distal extremity swelling with pitting edema, and distal tenosynovitis can be present. Arthritis does not lead to erosions, deformities, or the development of rheumatoid arthritis. [24] Distal extremity swelling with pitting edema responds promptly to glucocorticoids. [25] An unusual distal manifestation is puffy edematous hand syndrome or remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome, comprised of explosive and abrupt clinical symptoms."}
{"id": "article-27416_19", "title": "Polymyalgia Rheumatica -- History and Physical", "content": "On physical examination, diffuse tenderness is usually\u00a0present over the shoulder without localization to specific structures. The pain usually restricts the shoulder's active range of motion,\u00a0while the passive range of motion can be normal when carefully examined. Restriction of neck and hip movements because of pain is also common. Muscle tenderness of the neck, arms, and thighs may be present. Although the patient might complain of nonspecific weakness,\u00a0muscle strength is usually intact on a more thorough examination. [20] Tenderness to muscle palpation is a nonspecific sign and usually relates to articular or bursal involvement.", "contents": "Polymyalgia Rheumatica -- History and Physical. On physical examination, diffuse tenderness is usually\u00a0present over the shoulder without localization to specific structures. The pain usually restricts the shoulder's active range of motion,\u00a0while the passive range of motion can be normal when carefully examined. Restriction of neck and hip movements because of pain is also common. Muscle tenderness of the neck, arms, and thighs may be present. Although the patient might complain of nonspecific weakness,\u00a0muscle strength is usually intact on a more thorough examination. [20] Tenderness to muscle palpation is a nonspecific sign and usually relates to articular or bursal involvement."}
{"id": "article-27416_20", "title": "Polymyalgia Rheumatica -- Evaluation -- Laboratory Studies", "content": "Elevated ESR is a common feature in PMR. The majority of authors consider ESR >40 mm/h significant. [26] [27] [28] ESR <40 mm/h is present in 5 to\u00a020% of patients. [29] One study revealed ESR values >104 mm/h in 20% of patients. [29] Patients with low ESR usually have a lower frequency of systemic features like fever, weight loss, and anemia. Response to therapy, the frequency of relapses, and the risk of developing GCA among these patients appear to be comparable with high ESR patients. [30] [31] CRP is also typically\u00a0elevated. CRP was found to be a more sensitive\u00a0indicator of disease activity in\u00a01 study, while ESR was found to be a superior predictor of relapse. [29]", "contents": "Polymyalgia Rheumatica -- Evaluation -- Laboratory Studies. Elevated ESR is a common feature in PMR. The majority of authors consider ESR >40 mm/h significant. [26] [27] [28] ESR <40 mm/h is present in 5 to\u00a020% of patients. [29] One study revealed ESR values >104 mm/h in 20% of patients. [29] Patients with low ESR usually have a lower frequency of systemic features like fever, weight loss, and anemia. Response to therapy, the frequency of relapses, and the risk of developing GCA among these patients appear to be comparable with high ESR patients. [30] [31] CRP is also typically\u00a0elevated. CRP was found to be a more sensitive\u00a0indicator of disease activity in\u00a01 study, while ESR was found to be a superior predictor of relapse. [29]"}
{"id": "article-27416_21", "title": "Polymyalgia Rheumatica -- Evaluation -- Laboratory Studies", "content": "Normocytic anemia and thrombocytosis can occur. Liver enzymes, especially alkaline phosphatase, are occasionally elevated. Serologic tests, such as an antinuclear antibody (ANA), rheumatoid factor (RF), and anti-citrullinated protein antibodies (Anti-CCP AB), are negative. The creatine phosphokinase (CPK) value is within the normal range.", "contents": "Polymyalgia Rheumatica -- Evaluation -- Laboratory Studies. Normocytic anemia and thrombocytosis can occur. Liver enzymes, especially alkaline phosphatase, are occasionally elevated. Serologic tests, such as an antinuclear antibody (ANA), rheumatoid factor (RF), and anti-citrullinated protein antibodies (Anti-CCP AB), are negative. The creatine phosphokinase (CPK) value is within the normal range."}
{"id": "article-27416_22", "title": "Polymyalgia Rheumatica -- Evaluation -- Ultrasound", "content": "Ultrasound is useful in diagnosing and monitoring treatment by assessing degrees of subacromial/subdeltoid bursitis, long-head biceps tenosynovitis, and glenohumeral synovitis. In\u00a01 study, a power Doppler\u00a0(PD) signal at subacromial/subdeltoid\u00a0bursae\u00a0was\u00a0observed in a third of PMR patients. The positive PD signal at diagnosis correlated with\u00a0an increased\u00a0frequency of relapses, but the persistence\u00a0of PD findings did not correlate with relapses/recurrences. [32] The 2012 ACR/EULAR PMR classification criteria include ultrasound. [33]", "contents": "Polymyalgia Rheumatica -- Evaluation -- Ultrasound. Ultrasound is useful in diagnosing and monitoring treatment by assessing degrees of subacromial/subdeltoid bursitis, long-head biceps tenosynovitis, and glenohumeral synovitis. In\u00a01 study, a power Doppler\u00a0(PD) signal at subacromial/subdeltoid\u00a0bursae\u00a0was\u00a0observed in a third of PMR patients. The positive PD signal at diagnosis correlated with\u00a0an increased\u00a0frequency of relapses, but the persistence\u00a0of PD findings did not correlate with relapses/recurrences. [32] The 2012 ACR/EULAR PMR classification criteria include ultrasound. [33]"}
{"id": "article-27416_23", "title": "Polymyalgia Rheumatica -- Evaluation -- Magnetic Resonance Imaging", "content": "Magnetic resonance imaging (MRI) helps depict bursitis, synovitis, and tenosynovitis in a similar way as\u00a0ultrasound does. However, it is more sensitive for hip and pelvic girdle findings. [34] Pelvic MRI frequently shows bilateral,\u00a0peri-tendinous enhancement of pelvic girdle tendons and occasional low-grade hip synovitis. An enhancement of the proximal origin of rectus femoris appears to be a highly specific and sensitive finding. [35]", "contents": "Polymyalgia Rheumatica -- Evaluation -- Magnetic Resonance Imaging. Magnetic resonance imaging (MRI) helps depict bursitis, synovitis, and tenosynovitis in a similar way as\u00a0ultrasound does. However, it is more sensitive for hip and pelvic girdle findings. [34] Pelvic MRI frequently shows bilateral,\u00a0peri-tendinous enhancement of pelvic girdle tendons and occasional low-grade hip synovitis. An enhancement of the proximal origin of rectus femoris appears to be a highly specific and sensitive finding. [35]"}
{"id": "article-27416_24", "title": "Polymyalgia Rheumatica -- Evaluation -- Positron Emission Tomography", "content": "A  positron emission tomography (PET) scan shows 18\u00a0F-fluorodeoxyglucose (FDG) uptake in shoulders, ischial tuberosities, greater trochanters, and glenohumeral and sternoclavicular joints in patients with PMR. [36] The role of PET in diagnosing large vessel vasculitis is described\u00a0in a discussion below with GCA.", "contents": "Polymyalgia Rheumatica -- Evaluation -- Positron Emission Tomography. A  positron emission tomography (PET) scan shows 18\u00a0F-fluorodeoxyglucose (FDG) uptake in shoulders, ischial tuberosities, greater trochanters, and glenohumeral and sternoclavicular joints in patients with PMR. [36] The role of PET in diagnosing large vessel vasculitis is described\u00a0in a discussion below with GCA."}
{"id": "article-27416_25", "title": "Polymyalgia Rheumatica -- Evaluation -- 2012 Provisional Classification Criteria for Polymyalgia Rheumatica: A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative", "content": "Patients aged 50 years or older with bilateral shoulder aching and abnormal C-reactive protein concentrations or ESR, plus at least\u00a04 points (without ultrasonography) or\u00a05 points or more (with ultrasonography) from Morning stiffness in excess of 45 minutes duration (2 points) Hip pain or restricted range of motion (1 point) Absence of rheumatoid factor or anti-citrullinated protein antibodies (2 points) Absence of other joint involvement (1 point) If ultrasonography is available, at least\u00a01 shoulder with subdeltoid bursitis, biceps tenosynovitis or glenohumeral synovitis (either posterior or axillary), and at least\u00a01 hip with synovitis or trochanteric bursitis (1 point) If ultrasonography is available, both shoulders with subdeltoid bursitis, biceps tenosynovitis, or glenohumeral synovitis (1 point) [33]", "contents": "Polymyalgia Rheumatica -- Evaluation -- 2012 Provisional Classification Criteria for Polymyalgia Rheumatica: A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative. Patients aged 50 years or older with bilateral shoulder aching and abnormal C-reactive protein concentrations or ESR, plus at least\u00a04 points (without ultrasonography) or\u00a05 points or more (with ultrasonography) from Morning stiffness in excess of 45 minutes duration (2 points) Hip pain or restricted range of motion (1 point) Absence of rheumatoid factor or anti-citrullinated protein antibodies (2 points) Absence of other joint involvement (1 point) If ultrasonography is available, at least\u00a01 shoulder with subdeltoid bursitis, biceps tenosynovitis or glenohumeral synovitis (either posterior or axillary), and at least\u00a01 hip with synovitis or trochanteric bursitis (1 point) If ultrasonography is available, both shoulders with subdeltoid bursitis, biceps tenosynovitis, or glenohumeral synovitis (1 point) [33]"}
{"id": "article-27416_26", "title": "Polymyalgia Rheumatica -- Evaluation -- 2012 Provisional Classification Criteria for Polymyalgia Rheumatica: A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative", "content": "\"A score=4 had 68% sensitivity and 78% specificity for discriminating all comparison subjects from PMR. The specificity was higher (88%) for discriminating shoulder conditions from PMR and lower (65%) for discriminating RA from PMR. Adding ultrasound, a score=5 had increased sensitivity to 66% and specificity to 81% . These criteria are not meant for diagnostic\u00a0purposes.\" [33]", "contents": "Polymyalgia Rheumatica -- Evaluation -- 2012 Provisional Classification Criteria for Polymyalgia Rheumatica: A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative. \"A score=4 had 68% sensitivity and 78% specificity for discriminating all comparison subjects from PMR. The specificity was higher (88%) for discriminating shoulder conditions from PMR and lower (65%) for discriminating RA from PMR. Adding ultrasound, a score=5 had increased sensitivity to 66% and specificity to 81% . These criteria are not meant for diagnostic\u00a0purposes.\" [33]"}
{"id": "article-27416_27", "title": "Polymyalgia Rheumatica -- Evaluation -- Polymyalgia Rheumatica and Giant Cell Arteritis", "content": "PMR and GCA\u00a0 frequently\u00a0overlap, and 20% of patients with PMR will get\u00a0diagnosed with GCA later. In biopsy-proven GCA, PMR features\u00a0are present in up to 50% of cases. [20]", "contents": "Polymyalgia Rheumatica -- Evaluation -- Polymyalgia Rheumatica and Giant Cell Arteritis. PMR and GCA\u00a0 frequently\u00a0overlap, and 20% of patients with PMR will get\u00a0diagnosed with GCA later. In biopsy-proven GCA, PMR features\u00a0are present in up to 50% of cases. [20]"}
{"id": "article-27416_28", "title": "Polymyalgia Rheumatica -- Evaluation -- Polymyalgia Rheumatica and Giant Cell Arteritis", "content": "In a study, among patients with PMR with the persistence of classic symptoms but no cranial GCA-like symptoms, a PET/CT\u00a0scan\u00a0was positive for large vessel vasculitis in 60.7%. Inflammatory low back pain, pelvic girdle, and diffuse lower limb pain were also predictors of positive\u00a0PET/CT\u00a0scans in these patients. [37] In another study, among patients who required higher doses of steroids or those who had atypical features like low-grade fever and weight loss, among others,\u00a048% had large vessel vasculitis on PET/CT. Elevated CRP values were found to correlate with large vessel vasculitis. [38] In a study where a random sample of 68 patients with \"pure\" PMR, histological examinations of biopsy specimens of the temporal artery revealed inflammatory changes in only\u00a03 patients (4.4%). [39]", "contents": "Polymyalgia Rheumatica -- Evaluation -- Polymyalgia Rheumatica and Giant Cell Arteritis. In a study, among patients with PMR with the persistence of classic symptoms but no cranial GCA-like symptoms, a PET/CT\u00a0scan\u00a0was positive for large vessel vasculitis in 60.7%. Inflammatory low back pain, pelvic girdle, and diffuse lower limb pain were also predictors of positive\u00a0PET/CT\u00a0scans in these patients. [37] In another study, among patients who required higher doses of steroids or those who had atypical features like low-grade fever and weight loss, among others,\u00a048% had large vessel vasculitis on PET/CT. Elevated CRP values were found to correlate with large vessel vasculitis. [38] In a study where a random sample of 68 patients with \"pure\" PMR, histological examinations of biopsy specimens of the temporal artery revealed inflammatory changes in only\u00a03 patients (4.4%). [39]"}
{"id": "article-27416_29", "title": "Polymyalgia Rheumatica -- Evaluation -- Polymyalgia Rheumatica and Giant Cell Arteritis", "content": "Patients with PMR should undergo evaluation for features suggestive of GCA at every\u00a0visit. A routine biopsy of\u00a0the temporal\u00a0artery\u00a0is not recommended.\u00a0Features like\u00a0the development of\u00a0a new\u00a0headache, vision and jaw\u00a0symptoms, tenderness and lack of pulses in the temporal\u00a0artery, lack of pulses in the periphery,\u00a0the persistence\u00a0of inflammatory\u00a0markers, high-grade fever, and refractoriness of classic\u00a0symptoms\u00a0are the red flags that should prompt\u00a0an urgent\u00a0evaluation for GCA\u00a0with imaging (chest/abdomen) such as CT angiography (CTA),\u00a0magnetic resonance angiography (MRA), or PET.", "contents": "Polymyalgia Rheumatica -- Evaluation -- Polymyalgia Rheumatica and Giant Cell Arteritis. Patients with PMR should undergo evaluation for features suggestive of GCA at every\u00a0visit. A routine biopsy of\u00a0the temporal\u00a0artery\u00a0is not recommended.\u00a0Features like\u00a0the development of\u00a0a new\u00a0headache, vision and jaw\u00a0symptoms, tenderness and lack of pulses in the temporal\u00a0artery, lack of pulses in the periphery,\u00a0the persistence\u00a0of inflammatory\u00a0markers, high-grade fever, and refractoriness of classic\u00a0symptoms\u00a0are the red flags that should prompt\u00a0an urgent\u00a0evaluation for GCA\u00a0with imaging (chest/abdomen) such as CT angiography (CTA),\u00a0magnetic resonance angiography (MRA), or PET."}
{"id": "article-27416_30", "title": "Polymyalgia Rheumatica -- Treatment / Management", "content": "Oral glucocorticoid (GC) therapy is a\u00a0well-proven\u00a0treatment. [40] [41] The essential points of\u00a0EULAR-ACR 2015 recommendations for management are summarized as follows:", "contents": "Polymyalgia Rheumatica -- Treatment / Management. Oral glucocorticoid (GC) therapy is a\u00a0well-proven\u00a0treatment. [40] [41] The essential points of\u00a0EULAR-ACR 2015 recommendations for management are summarized as follows:"}
{"id": "article-27416_31", "title": "Polymyalgia Rheumatica -- Treatment / Management", "content": "Administer 12.5 to 25\u00a0mg daily prednisone equivalent\u00a0as an initial therapy. Taper GCs gradually. Taper to an oral dose of 10 mg daily prednisone equivalent within 4 to 8 weeks. Once remission\u00a0is achieved, taper daily oral prednisone by 1 mg every\u00a04 weeks\u00a0until discontinuation Treat for a minimum of 12 months. For relapse, increase oral prednisone to the pre-relapse dose and decrease it gradually (within 4 to 8 weeks) to the dose at which the relapse occurred. Individualize\u00a0dose-tapering schedules based on regularly monitoring patient disease activity, laboratory markers, and adverse events. Administer lower doses of 7.5 to 10 mg daily for smaller patients with mild symptoms or brittle diabetes. Consider early introduction of methotrexate (MTX)\u00a0in addition to GCs, particularly in patients at high risk of relapse and/or prolonged therapy, as well as in cases with risk factors, comorbidities, and/or concomitant medications where GC-related adverse events are more likely to occur.", "contents": "Polymyalgia Rheumatica -- Treatment / Management. Administer 12.5 to 25\u00a0mg daily prednisone equivalent\u00a0as an initial therapy. Taper GCs gradually. Taper to an oral dose of 10 mg daily prednisone equivalent within 4 to 8 weeks. Once remission\u00a0is achieved, taper daily oral prednisone by 1 mg every\u00a04 weeks\u00a0until discontinuation Treat for a minimum of 12 months. For relapse, increase oral prednisone to the pre-relapse dose and decrease it gradually (within 4 to 8 weeks) to the dose at which the relapse occurred. Individualize\u00a0dose-tapering schedules based on regularly monitoring patient disease activity, laboratory markers, and adverse events. Administer lower doses of 7.5 to 10 mg daily for smaller patients with mild symptoms or brittle diabetes. Consider early introduction of methotrexate (MTX)\u00a0in addition to GCs, particularly in patients at high risk of relapse and/or prolonged therapy, as well as in cases with risk factors, comorbidities, and/or concomitant medications where GC-related adverse events are more likely to occur."}
{"id": "article-27416_32", "title": "Polymyalgia Rheumatica -- Treatment / Management", "content": "Clinical trials used MTX at oral doses of 7.5 to 10 mg/week. [40] A study shows\u00a0leflunomide\u00a0is an effective steroid-sparing agent that can also be used in PMR. [42] It can be an alternative if the patient is not able to take MTX for various reasons.\u00a0Sparse data for\u00a0azathioprine exist for treating PMR, and\u00a0its use may be an option in cases with contraindications for methotrexate. [43] EULAR-ACR 2015 recommendations advise against the use of anti-TNF agents. [40]", "contents": "Polymyalgia Rheumatica -- Treatment / Management. Clinical trials used MTX at oral doses of 7.5 to 10 mg/week. [40] A study shows\u00a0leflunomide\u00a0is an effective steroid-sparing agent that can also be used in PMR. [42] It can be an alternative if the patient is not able to take MTX for various reasons.\u00a0Sparse data for\u00a0azathioprine exist for treating PMR, and\u00a0its use may be an option in cases with contraindications for methotrexate. [43] EULAR-ACR 2015 recommendations advise against the use of anti-TNF agents. [40]"}
{"id": "article-27416_33", "title": "Polymyalgia Rheumatica -- Treatment / Management", "content": "Most data for using tocilizumab (TCZ) in PMR\u00a0come from PMR coexisting with GCA. Case series and open-label studies have shown TCZ is useful in PMR with relapse or insufficient response to GC. [44] An open-label study suggested that relapse-free remission without GC treatment at\u00a06 months was achievable in newly diagnosed patients with PMR. [45] Randomized controlled trials\u00a0are needed\u00a0to evaluate if TCZ is routinely beneficial in certain patients with PMR.", "contents": "Polymyalgia Rheumatica -- Treatment / Management. Most data for using tocilizumab (TCZ) in PMR\u00a0come from PMR coexisting with GCA. Case series and open-label studies have shown TCZ is useful in PMR with relapse or insufficient response to GC. [44] An open-label study suggested that relapse-free remission without GC treatment at\u00a06 months was achievable in newly diagnosed patients with PMR. [45] Randomized controlled trials\u00a0are needed\u00a0to evaluate if TCZ is routinely beneficial in certain patients with PMR."}
{"id": "article-27416_34", "title": "Polymyalgia Rheumatica -- Treatment / Management", "content": "Vitamin D and calcium supplementation are routine recommendations for patients on long-term steroids. Bisphosphonate prophylaxis is recommended for patients in moderate\u00a0to high fracture risk categories, including patients\u00a0older than 40 years with a fracture risk assessment (FRAX) score of >1% and >10% risk of hip and major osteoporotic fracture, respectively. [46]", "contents": "Polymyalgia Rheumatica -- Treatment / Management. Vitamin D and calcium supplementation are routine recommendations for patients on long-term steroids. Bisphosphonate prophylaxis is recommended for patients in moderate\u00a0to high fracture risk categories, including patients\u00a0older than 40 years with a fracture risk assessment (FRAX) score of >1% and >10% risk of hip and major osteoporotic fracture, respectively. [46]"}
{"id": "article-27416_35", "title": "Polymyalgia Rheumatica -- Treatment / Management", "content": "Close follow-up is recommended.\u00a0Guidelines published by BSR and BHPR\u00a0recommend follow-up at weeks 0, 1 to 3, and 6, then months 3, 6, 9, and 12 in the first year (with extra visits for relapses or adverse events). [47] It seems prudent to follow up with patients every\u00a03 months until remission and, after that, every\u00a06 months to\u00a01 year to monitor for recurrence. CRP and ESR help monitor disease activity, and some data indicate CRP as a more sensitive marker. [29]", "contents": "Polymyalgia Rheumatica -- Treatment / Management. Close follow-up is recommended.\u00a0Guidelines published by BSR and BHPR\u00a0recommend follow-up at weeks 0, 1 to 3, and 6, then months 3, 6, 9, and 12 in the first year (with extra visits for relapses or adverse events). [47] It seems prudent to follow up with patients every\u00a03 months until remission and, after that, every\u00a06 months to\u00a01 year to monitor for recurrence. CRP and ESR help monitor disease activity, and some data indicate CRP as a more sensitive marker. [29]"}
{"id": "article-27416_36", "title": "Polymyalgia Rheumatica -- Treatment / Management", "content": "Relapses often entail increased ESR and CRP and the return of symptoms. Increased risk of relapse is found to correlate with a higher initial dose of steroid used, rapid steroid tapering, HLA-DRB1*0401, and persistently high inflammatory markers. [13] [48] [49] Managing relapses can be challenging. The usual approach is as follows: For patients with recurrent symptoms developing following discontinuation of GCs and accompanied by an elevation in the CRP and/or ESR, GCs can be restarted at the original dose that managed symptoms. For patients who relapse several times, it is reasonable to lengthen the\u00a0interval between dose reductions to\u00a06 to\u00a08 weeks.", "contents": "Polymyalgia Rheumatica -- Treatment / Management. Relapses often entail increased ESR and CRP and the return of symptoms. Increased risk of relapse is found to correlate with a higher initial dose of steroid used, rapid steroid tapering, HLA-DRB1*0401, and persistently high inflammatory markers. [13] [48] [49] Managing relapses can be challenging. The usual approach is as follows: For patients with recurrent symptoms developing following discontinuation of GCs and accompanied by an elevation in the CRP and/or ESR, GCs can be restarted at the original dose that managed symptoms. For patients who relapse several times, it is reasonable to lengthen the\u00a0interval between dose reductions to\u00a06 to\u00a08 weeks."}
{"id": "article-27416_37", "title": "Polymyalgia Rheumatica -- Differential Diagnosis", "content": "PMR has nonspecific features that many other entities can mimic. Other entities should be excluded from investigations before diagnosing PMR, as deemed necessary by clinical suspicion. [22] [50] Differential diagnoses are as follows: Crown dens syndrome [51] Hypothyroidism Obstructive sleep apnea Depression Viral infections\u00a0such as EBV, hepatitis, human immunodeficiency virus, parvovirus B19 Systemic bacterial infections, septic arthritis Cancer Diabetes Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome [52]", "contents": "Polymyalgia Rheumatica -- Differential Diagnosis. PMR has nonspecific features that many other entities can mimic. Other entities should be excluded from investigations before diagnosing PMR, as deemed necessary by clinical suspicion. [22] [50] Differential diagnoses are as follows: Crown dens syndrome [51] Hypothyroidism Obstructive sleep apnea Depression Viral infections\u00a0such as EBV, hepatitis, human immunodeficiency virus, parvovirus B19 Systemic bacterial infections, septic arthritis Cancer Diabetes Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome [52]"}
{"id": "article-27416_38", "title": "Polymyalgia Rheumatica -- Prognosis", "content": "PMR has an excellent prognosis when the\u00a0diagnosis is made promptly, and appropriate treatment is initiated. Mortality among individuals with\u00a0PMR is not significantly increased compared to the general population. [53]", "contents": "Polymyalgia Rheumatica -- Prognosis. PMR has an excellent prognosis when the\u00a0diagnosis is made promptly, and appropriate treatment is initiated. Mortality among individuals with\u00a0PMR is not significantly increased compared to the general population. [53]"}
{"id": "article-27416_39", "title": "Polymyalgia Rheumatica -- Complications", "content": "According to different studies,\u00a0PMR patients have an increased risk of cardiovascular diseases by 1.15 to 2.70. Premature atherosclerosis resulting from chronic inflammation is the most likely cause of premature CAD. [54]", "contents": "Polymyalgia Rheumatica -- Complications. According to different studies,\u00a0PMR patients have an increased risk of cardiovascular diseases by 1.15 to 2.70. Premature atherosclerosis resulting from chronic inflammation is the most likely cause of premature CAD. [54]"}
{"id": "article-27416_40", "title": "Polymyalgia Rheumatica -- Complications", "content": "A cancer association with PMR is not entirely clear. [55] In a study of the increased risk of lymphoplasmacytic lymphoma, Waldenstrom\u00a0macroglobulinemia correlated with PMR with an odds ratio (OR) of 2.9. [56]", "contents": "Polymyalgia Rheumatica -- Complications. A cancer association with PMR is not entirely clear. [55] In a study of the increased risk of lymphoplasmacytic lymphoma, Waldenstrom\u00a0macroglobulinemia correlated with PMR with an odds ratio (OR) of 2.9. [56]"}
{"id": "article-27416_41", "title": "Polymyalgia Rheumatica -- Complications", "content": "PMR patients have a higher chance of developing inflammatory arthritis. Features of small joint synovitis, younger age, and positive anti-CCP positivity\u00a0in patients with PMR were associated with the risk of developing inflammatory arthritis. [57]", "contents": "Polymyalgia Rheumatica -- Complications. PMR patients have a higher chance of developing inflammatory arthritis. Features of small joint synovitis, younger age, and positive anti-CCP positivity\u00a0in patients with PMR were associated with the risk of developing inflammatory arthritis. [57]"}
{"id": "article-27416_42", "title": "Polymyalgia Rheumatica -- Consultations", "content": "Referral to a rheumatologist is suggested if there are atypical features (eg, presenting fever, younger patients),\u00a0an inadequate response to initial\u00a0GC treatment, prominent peripheral arthritis, or difficulties with\u00a0GC tapering.", "contents": "Polymyalgia Rheumatica -- Consultations. Referral to a rheumatologist is suggested if there are atypical features (eg, presenting fever, younger patients),\u00a0an inadequate response to initial\u00a0GC treatment, prominent peripheral arthritis, or difficulties with\u00a0GC tapering."}
{"id": "article-27416_43", "title": "Polymyalgia Rheumatica -- Deterrence and Patient Education", "content": "Deterrence and prevention strategies for PMR primarily revolve around early recognition, accurate diagnosis, and timely initiation of appropriate treatment. Since PMR predominantly affects individuals older than 50 years, proactive screening and awareness campaigns among this age group may facilitate early identification of symptoms, enabling prompt medical intervention. Additionally, raising awareness among healthcare professionals about the clinical features and diagnostic criteria for PMR can improve detection rates.", "contents": "Polymyalgia Rheumatica -- Deterrence and Patient Education. Deterrence and prevention strategies for PMR primarily revolve around early recognition, accurate diagnosis, and timely initiation of appropriate treatment. Since PMR predominantly affects individuals older than 50 years, proactive screening and awareness campaigns among this age group may facilitate early identification of symptoms, enabling prompt medical intervention. Additionally, raising awareness among healthcare professionals about the clinical features and diagnostic criteria for PMR can improve detection rates."}
{"id": "article-27416_44", "title": "Polymyalgia Rheumatica -- Deterrence and Patient Education", "content": "Implementing routine monitoring of inflammatory markers, such as ESR and CRP, in older populations with musculoskeletal complaints can aid in early detection. Moreover, educating the public on lifestyle factors that may impact inflammatory conditions and promoting regular physical activity and a healthy diet may play a role in preventing or mitigating the severity of PMR.", "contents": "Polymyalgia Rheumatica -- Deterrence and Patient Education. Implementing routine monitoring of inflammatory markers, such as ESR and CRP, in older populations with musculoskeletal complaints can aid in early detection. Moreover, educating the public on lifestyle factors that may impact inflammatory conditions and promoting regular physical activity and a healthy diet may play a role in preventing or mitigating the severity of PMR."}
{"id": "article-27416_45", "title": "Polymyalgia Rheumatica -- Deterrence and Patient Education", "content": "Patients should be thoroughly counseled regarding the risks and benefits of\u00a0GC treatment. Patients should also be encouraged to adhere to their medication regimens and long-term follow-up to minimize the risk of disease recurrence and potential side effects of medications. Patients should also be made aware of the importance of taking calcium and vitamin D supplements.", "contents": "Polymyalgia Rheumatica -- Deterrence and Patient Education. Patients should be thoroughly counseled regarding the risks and benefits of\u00a0GC treatment. Patients should also be encouraged to adhere to their medication regimens and long-term follow-up to minimize the risk of disease recurrence and potential side effects of medications. Patients should also be made aware of the importance of taking calcium and vitamin D supplements."}
{"id": "article-27416_46", "title": "Polymyalgia Rheumatica -- Deterrence and Patient Education", "content": "Overall, a multifaceted approach that combines public awareness, healthcare provider education, and proactive screening holds promise for enhancing deterrence and prevention efforts against the impact of PMR.", "contents": "Polymyalgia Rheumatica -- Deterrence and Patient Education. Overall, a multifaceted approach that combines public awareness, healthcare provider education, and proactive screening holds promise for enhancing deterrence and prevention efforts against the impact of PMR."}
{"id": "article-27416_47", "title": "Polymyalgia Rheumatica -- Pearls and Other Issues", "content": "Key facts to keep in mind regarding polymyalgia rheumatica\u00a0are as follows: Asymptomatic patients with elevations in the ESR and/or CRP do not require increased doses of GCs. Fibromyalgia-like symptoms,\u00a0such as widespread muscle pain associated with fatigue and stiffness, have been reported during the tapering phase of longstanding\u00a0GC therapy in PMR patients and can be managed by chronic low doses of GCs. Physical therapy can benefit an\u00a0older adult who has become deconditioned but has no role in initial management. Nonsteroidal anti-inflammatory drugs (NSAIDs) have no therapeutic role in the initial management of PMR.", "contents": "Polymyalgia Rheumatica -- Pearls and Other Issues. Key facts to keep in mind regarding polymyalgia rheumatica\u00a0are as follows: Asymptomatic patients with elevations in the ESR and/or CRP do not require increased doses of GCs. Fibromyalgia-like symptoms,\u00a0such as widespread muscle pain associated with fatigue and stiffness, have been reported during the tapering phase of longstanding\u00a0GC therapy in PMR patients and can be managed by chronic low doses of GCs. Physical therapy can benefit an\u00a0older adult who has become deconditioned but has no role in initial management. Nonsteroidal anti-inflammatory drugs (NSAIDs) have no therapeutic role in the initial management of PMR."}
{"id": "article-27416_48", "title": "Polymyalgia Rheumatica -- Enhancing Healthcare Team Outcomes", "content": "The management of PMR is best\u00a0accomplished using an interprofessional team approach. Patients with PMR usually receive an initial evaluation\u00a0by primary care clinicians. A low threshold for suspicion, timely referral to rheumatology, and excluding giant cell arteritis are essential aspects in the initial care of these patients. PMR has a long list of differentials and mimickers, and diagnosis\u00a0may be even more challenging if the patient already\u00a0has\u00a01 of those as a coexisting condition.", "contents": "Polymyalgia Rheumatica -- Enhancing Healthcare Team Outcomes. The management of PMR is best\u00a0accomplished using an interprofessional team approach. Patients with PMR usually receive an initial evaluation\u00a0by primary care clinicians. A low threshold for suspicion, timely referral to rheumatology, and excluding giant cell arteritis are essential aspects in the initial care of these patients. PMR has a long list of differentials and mimickers, and diagnosis\u00a0may be even more challenging if the patient already\u00a0has\u00a01 of those as a coexisting condition."}
{"id": "article-27416_49", "title": "Polymyalgia Rheumatica -- Enhancing Healthcare Team Outcomes", "content": "Once\u00a0PMR is diagnosed, the pharmacist should be consulted regarding dosing and potential interactions with the patient's drug regimen. The pharmacist can also counsel patients regarding their medications and warn them of possible adverse effects. If the pharmacist notes any concerns, he should inform the prescriber immediately for therapeutic changes.", "contents": "Polymyalgia Rheumatica -- Enhancing Healthcare Team Outcomes. Once\u00a0PMR is diagnosed, the pharmacist should be consulted regarding dosing and potential interactions with the patient's drug regimen. The pharmacist can also counsel patients regarding their medications and warn them of possible adverse effects. If the pharmacist notes any concerns, he should inform the prescriber immediately for therapeutic changes."}
{"id": "article-27416_50", "title": "Polymyalgia Rheumatica -- Enhancing Healthcare Team Outcomes", "content": "Nursing likewise plays a crucial role in these cases, as they will have more patient contact, can counsel the patient about their condition, and must report any concerns or changes in the patient's condition to the clinicians immediately, noting the changes and reasons for concern, so the clinicians can follow-up and make any therapeutic changes necessary.", "contents": "Polymyalgia Rheumatica -- Enhancing Healthcare Team Outcomes. Nursing likewise plays a crucial role in these cases, as they will have more patient contact, can counsel the patient about their condition, and must report any concerns or changes in the patient's condition to the clinicians immediately, noting the changes and reasons for concern, so the clinicians can follow-up and make any therapeutic changes necessary."}
{"id": "article-27416_51", "title": "Polymyalgia Rheumatica -- Enhancing Healthcare Team Outcomes", "content": "Essential aspects of long-term management include frequent follow-up, vigilance\u00a0in detecting developing GCA, and managing relapse or refractory disease. Strong coordination and peer-to-peer communication within the interprofessional team are essential for good outcomes and an optimal care model.", "contents": "Polymyalgia Rheumatica -- Enhancing Healthcare Team Outcomes. Essential aspects of long-term management include frequent follow-up, vigilance\u00a0in detecting developing GCA, and managing relapse or refractory disease. Strong coordination and peer-to-peer communication within the interprofessional team are essential for good outcomes and an optimal care model."}
{"id": "article-27416_52", "title": "Polymyalgia Rheumatica -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Polymyalgia Rheumatica -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}